Introduction
Since its discovery over a quarter of a century ago, work on the tumour suppressor protein p53 has produced nearly 40 000 publications. This vast amount of work on one protein is arguably justified by the importance of p53 in cancer biology, as illustrated by the frequency with which p53 function is lost during tumour development. Approximately 50% of all malignancies carry a p53 mutation, and of those tumours that do not have mutated p53, a large proportion have inactivated p53 function by another mechanism (Hainaut and Hollstein, 2000; Bykov and Wiman, 2003) . Taken together, p53 function is lost in almost all tumours. The importance of p53 as a tumour suppressor is illustrated by the observation that many individuals affected by Li Fraumeni syndrome -and so displaying an abnormally high and early incidence of tumour development -suffer a germline mutation in p53 (Malkin et al., 1990; Srivastava et al., 1990) . Furthermore, mouse studies have corroborated the importance of p53 in tumour development; p53 null mice can develop normally but nearly all develop cancer before 6 months of age (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994) . Taken together, a role for p53 as a key player in the inhibition of tumour development is beyond doubt. However, there is growing evidence that p53 also contributes to other pathologies beyond cancer -including a possible contribution in determining longevity -making it unlikely that the high degree of interest in p53 will wane.
The downstream response to p53 activation
The p53 protein is a transcription factor that regulates the expression of a large number of target genes (Vogelstein et al., 2000) . Through this mechanism p53 can induce a number of different responses, ranging from the induction of cell cycle arrest, cell death and senescence to protective antioxidant activities, DNA repair and the control of mitochondrial respiration.
One of the first transcriptional targets of p53 to be identified was the cyclin dependent kinase (CDK) inhibitor p21
Waf1/Cip1 (El-Deiry et al., 1994) . CDKs play an important role in regulating progression through the cell cycle, and the inhibition of CDK activity by p21 Waf1/Cip1 results in a cell cycle arrest (reviewed in Sherr and Roberts, 1999) . Thus, p53 can effectively cause cells to stop proliferating, which -among other things -allows for the repair of any damaged DNA, preventing mutations from being passed on to daughter cells. Interestingly, a direct role for p53 in DNA repair has also been demonstrated (reviewed in Gatz and Wiesmuller (2006) ). Recently, other activities of p53 that can inhibit the acquisition of potentially oncogenic mutations have been described. Several studies have shown an antioxidant role for p53 resulting from the expression of target genes that reduce intracellular reactive oxygen species (ROS) levels and so prevent genotoxic damage (Budanov et al., 2004; Yoon et al., 2004; Sablina et al., 2005; Bensaad et al., 2006) . This function of p53 appears to be important even in the absence of acute, high levels of stress -and probably reflects a response to lower levels of constitutive stress that accompany everyday life of complex multicellular organisms (Sablina et al., 2005) . These antioxidant functions of p53 are linked with enhanced survival of cells expressing p53, and so seem to be at odds with another important activity of p53, which is to induce cell death through apoptosis or autophagy. Why would p53 induce repair of a cell that it then targets for destruction? While some of the answer clearly lies in cell-type dependent differences, an interesting model is emerging where p53 behaves differently depending on the severity of the stress (Bensaad and Vousden, 2005) . In response to low, constitutive stress, p53 activates expression of genes that drive a temporary cell cycle arrest, allowing for the removal of intracellular ROS and repair of any damage that may have occurred. But when the stress-induced damage is too severe for the cell to recover, p53 initiates programmed cell death -so eliminating cells that may have acquired irreparable and potentially oncogenic alterations. The transcriptional targets of p53 include a number of pro-apoptotic proteins such as the BH3 only proteins Puma and Noxa (Oda et al., 2000; Nakano and Vousden, 2001; Yu et al., 2001) . These proteins function by inducing the loss of inner mitochondrial membrane potential, leading to the release of cytochrome C and other apoptogenic factors and the activation of the caspase cascade that results in apoptotic cell death (Jeffers et al., 2003; Villunger et al., 2003; Yu et al., 2003 and reviewed in Danial and Korsmeyer, 2004) . Activation of autophagy by the p53-induced protein DRAM (damage-regulated autophagy modulator) has also been described to be an important contributor of the apoptotic response (Crighton et al., 2006) .
Inkeeping with its function as a transcription factor, p53 is predominately a nuclear protein. However, a fraction of p53 can be found in the cytoplasm. Recent studies have demonstrated an unexpected transcriptionally independent function for this pool of p53 as a BH3-only protein, inducing apoptosis by directly binding to the pro-apoptotic proteins Bax and Bak, as well as the anti-apoptotic proteins like BclxL (Mihara et al., 2003; Chipuk et al., 2004; Leu et al., 2004) . Interestingly PUMA, a transcriptional target of p53, can activate this cytoplasmic function of p53 (Chipuk et al., 2005) , suggesting that both transcriptional and non-transcriptional activities of p53 are important for the induction of cell death (reviewed in Yee and Vousden, 2005) .
Regulation of p53 function
The anti-proliferative activities of p53 play an important role in tumour suppression, but require strong negative regulation to allow for normal growth and development. Not surprisingly, this regulation of p53 takes many forms, including the regulation of expression, protein stability and protein activity. Many post-transcriptional modifications of p53 have been described including phosphorylation, acetylation, methylation, glycosylation, ribosylation and, most recently, O-GlcNAcylation (Bode and Dong, 2004; Yang et al., 2006c) . However, in vivo models have suggested that these modifications play only very subtle, modulatory roles in regulating p53 function (Toledo and Wahl, 2006) . The interaction of p53 with proteins that control p53 function, either directly or through the regulation of p53 stability, appears to be key in turning on and off the p53 response.
Regulation of p53 protein stability p53 is degraded via the proteasome by a predominately ubiquitin-dependent mechanism, and a number of ubiquitin ligases that promote the ubiquitination and subsequent degradation of p53 have been identified (Table 1) .
By far the best studied of these is Mdm2 (sometimes referred to as HDM2 in humans) -a RING finger protein that is essential to regulate p53 and allow survival during normal development (Jones et al., 1995; Montes de Oca Luna et al., 1995) . Mdm2 functions as a ubiquitin ligase, in which the RING domain is necessary to promote the ubiquitination and degradation of its target proteins, including p53 (Fang et al., 2000) . Mdm2 is itself a transcriptional target of p53 (Zauberman et al., 1993) , establishing a negative feedback loop in which Mdm2 can keep the physiological levels of p53 low, and contribute to the recovery phase at the end of a p53 response. While Mdm2 is sufficient to target p53 for degradation, there is good evidence that it does not function alone. Several proteins have recently been shown to cooperate with Mdm2 in the regulation of p53. The Yin Yang 1 (YY1) transcription factor, a protein that plays a key role in development, can increase the interaction between p53 and Mdm2, so enhancing Mdm2-dependent p53 poly-ubiquitination and degradation (Gronroos et al., 2004; Sui et al., 2004) .
A similar function has also been attributed to gankyrin, with the gankyrin/Mdm2 interaction promoting p53 binding and degradation (Higashitsuji et al., 2005a, b) . The mechanism underlying this activity of gankyrin is suggested by the observation that gankyrin associates with the S6 proteasomal ATPase. This interaction of gankyrin, Mdm2 and p53 also promotes increased association of the Mdm2-p53 complex to the 26S proteasome, and so promotes more efficient degradation of p53 and Mdm2 (Dawson et al., 2002; Higashitsuji et al., 2005a) . The frequent overexpression of gankyrin in hepatocellular carcinomas may therefore be an important mechanism for inactivating the p53 pathway in these tumours (Fu et al., 2002; Nagao et al., 2003; Higashitsuji et al., 2005b) . p300/CBP has also been shown to cooperate with Mdm2 to promote poly-ubiquitination of p53 (Grossman et al., 2003) . p300 has a well established role in promoting acetylation of p53, thereby enhancing its transcriptional activity (Grossman, 2001 ). However, a recent report has suggested that under most conditions Mdm2 can only promote the mono-ubiquitination of p53, and that the binding of p300 to Mdm2 is necessary for efficient poly-ubiquitination to occur (Grossman et al., 2003) . As poly-ubiquitination is required for recognition by the proteasome and degradation (reviewed in Weissman, 2001 ), proteins like p300 may be key in controlling p53 stability.
The recent identification of HAUSP (herpesvirus associated ubiquitin-specific protease) and other deubiquitinating (DUB) enzymes has added a further level of complexity to the regulation of p53 stability. Although HAUSP can de-ubiquitinate p53 directly (Li et al., 2002) , its principal function in the p53 pathway seems to be in the de-ubiquitination and stabilization of Mdm2 (Cummins and Vogelstein, 2004; Li et al., 2004) , resulting in enhanced degradation of p53. This modification is influenced by yet another protein, Daxx (death domain-associated protein), which forms a complex with Mdm2 and HAUSP, preventing the auto-ubiquitination of Mdm2 and thus promoting p53 degradation .
Of the other p53 ubiquitin ligases listed in Table 1 , Cop1, Pirh2, HectH9/MULE/ARF-BP1, E6AP and CHIP have all been shown to promote the degradation of p53 under varying conditions. Like Mdm2, Cop1 and Pirh2 also reside in negative feedback loops by being themselves transcriptional targets of p53 (Leng et al., 2003; Dornan et al., 2004) . While each of these ligases have been shown to regulate p53 stability in cells, mouse knockout studies will prove useful in determining their relative contribution to regulating p53 levels in vivo.
Finally, it has been shown that p53 can be degraded through an ubiquitin-independent mechanism as well. This pathway involves the 20S proteasome and is regulated by the NAD(P)H quinone oxidoreductase 1 (NQO1) (Asher et al., 2001) . The major pool of NQO1 can be found at the 20S proteasome, where it is thought to act as a gatekeeper. NQO1 can bind directly to p53, preventing it from being degraded in a 20S proteasomal manner. Genotoxic insults such as ionizing radiation lead to increased association between p53 and NQO1, and so to p53 stabilization (Asher and Shaul, 2005) .
SUMOylation and NEDDylation
While ubiquitination is the most studied protein modification of p53, the ubiquitin-like proteins SUMO-1 and Nedd8 can also be conjugated to p53 and modify its function (recently reviewed in Watson and Irwin (2006) ). As in ubiquitination, specific E3 ligases mediate the modification of p53 by SUMO-1 and Nedd8. Interestingly, Mdm2 also functions as an E3 for Nedd8 -promoting the conjugation of Nedd8 to three C-terminal lysines in p53 that are also targeted by ubiquitination (Xirodimas et al., 2004) . Neddylation of p53 can also be mediated by FBX011, a component of the SCF complex (Abida et al., 2006) . A number of proteins have been shown to function in the regulation of p53 SUMOylation, including the family of PIAS ligases (PIAS1, PIASxb and PIASy), (Kahyo et al., 2001; Nelson et al., 2001; Megidish et al., 2002; Schmidt and Muller, 2002) . While Neddylation appears to result in the inhibition of p53 function, there have been conflicting reports of the effect of SUMOylation (reviewed in Melchior and Hengst (2002) ). However, recent studies have demonstrated that SUMO-modification can activate p53 and so contribute to the induction of p53-mediated senescence and apoptosis (Bischof et al., 2006; Li et al., 2006) . Whereas the modification by SUMO-1 and Nedd8 does not appear to modulate p53 stability directly, SUMOylation can mediate an indirect effect by regulating Mdm2's stability and function .
MdmX
Another key regulator of p53 is MdmX (Mdm4), a structural relative of Mdm2. Like Mdm2, MdmX contains an N-terminal p53-binding domain and a RING domain at its C-terminus (Shvarts et al., 1996) . However, MdmX does not show E3 activity (Jackson and Berberich, 2000; Stad et al., 2001) and functions predominantly by directly inhibiting p53's transcriptional activity (Shvarts et al., 1996; Francoz et al., 2006) . Although this function of MdmX is independent of Mdm2 (Francoz et al., 2006; Xiong et al., 2006) , there are some interesting levels of cross talk between these two proteins. MdmX and Mdm2 hetero-oligomerize through their RING domains (Sharp et al., 1999; Tanimura et al., 1999) , which results in the stabilization of Mdm2 (Stad et al., 2001; Gu et al., 2002) or the Mdm2-mediated degradation of MdmX (de Graaf et al., 2003; Kawai et al., 2003; Pan and Chen, 2003) , depending on the relative expression levels of the two proteins. Recent studies have also suggested that a heteromeric complex between Mdm2 and MdmX can retain ubiquitin ligase activity, suggesting that despite the inactive RING, MdmX may play a direct role in E3 activity Uldrijan et al., 2006) (Figure 1 ).
p53 subcellular localization
As might be expected for a protein with both nuclear and cytoplasmic functions, the subcellular localization of p53 can also play an important role in regulating its activity. Mdm2 can promote the nuclear export of p53 in a ubiquitin-ligase-dependent manner (Boyd et al., 2000; Lohrum et al., 2001; Li et al., 2003) . Mdm2 and p53 do not leave the nucleus together; rather it seems that mono-ubiquitination of p53 by Mdm2 leads to an unmasking of the nuclear export sequence within the C-terminus of p53 (Gu et al., 2001; Li et al., 2003) . Two other ubiquitin ligases also promote the cytoplasmic localization of p53, Cullin 7 (CUL7) and WWP1 (Andrews et al., 2006; . Neither of these E3s target p53 for degradation, but result in the accumulation of transcriptionally inactive p53 in the cytoplasm. Similarly, regulation of p53 ubiquitination by the E2 ubiquitin-conjugating enzyme Ubc13 has been shown to drive nuclear export of p53 . In a further twist, ubiquitination of p53 by E4F1 results in neither degradation nor nuclear export, but enhances transcriptional activation resulting selectively in the cell cycle arrest response (Le Cam et al., 2006) .
While cytoplasmic sequestration inhibits p53 -and is seen as a mechanisms to inactivate p53 in some breast cancers and neuroblastomas (Moll et al., 1992 (Moll et al., , 1995 the relocalization of at least some p53 from the nucleus is important for the cytoplasmic functions of p53. The effect of Mdm2 on p53 function is therefore complexwhile degradation of p53 clearly inactivates all functions, some level of Mdm2-mediated ubiquitination may be required for export and full apoptotic activity (Moll et al., 2006) .
A delicate balance
In both humans and mice, there is exquisite sensitivity to modulation of the p53 pathway, with relatively modest changes in p53 function resulting in profound effects. This has been highlighted by studies investigating the consequences of modifying the naturally occurring ratio between Mdm2 and p53. Increasing potential p53 activity, by adding an extra copy of p53 or reducing (but not eliminating) expression of Mdm2, resulted in apparently normal mice that were resistant to tumour development (Garcia-Cao et al., 2002 , 2006 . However, mice in which overexpression of p53 was accompanied by an imbalance in the normal ratios of different p53 isoforms, showed an alarming premature aging phenotype (Tyner et al., 2002; Maier et al., 2004) that may be associated with p53 functions of driving senescence and modulating the insulin pathway. The contribution of p53 to aging is still not clear, but it would seem that just enough p53 -neither too much nor too little -is required for optimal longevity (Mendrysa and Perry, 2006; Poyurovsky and Prives, 2006) .
The consequences of small changes in p53 activity have also been highlighted by the study of polymorphisms in the p53 pathway in humans. A SNP was recently discovered at position 309 of the first intron of Mdm2 (Bond et al., 2004) . This polymorphism alters the affinity of an SP1 transcription factor-binding site, and results in a slightly higher expression of Mdm2 in these individuals, dampening the activation of p53 in response to DNA damage. While this results in a relatively modest decrease in the activation of p53, there is a clear effect on tumour susceptibility in individuals carrying this SNP.
A number of polymorphisms of p53 have also been described, including a SNP at amino acid position 72 that changes the amino acid from a proline (P) to an arginine (R). The P72 variant is somewhat better at promoting a cell cycle arrest, while the R72 variant is better at inducing apoptosis (Pim and Banks, 2004 ) and as such, tumours carrying the R72 variant are generally more responsive to treatment and have a better survival rate, when compared to tumours carrying the P72 variant (reviewed in Pietsch et al. (2006) ).
Stress induced stabilization and activation of p53
Efficient control of p53 is critical to allow normal cell growth. But clearly these brakes to p53 function must be released in order for p53 to act as an effective tumour suppressor, and a number of mechanisms that lead to the stabilization and activation of p53 have been identified. A growing number of stress signals that can lead to p53 activation are being identified, including DNA damage, oncogene activation and more. Interestingly, different stress signals seem to utilize different pathways to allow for the activation of p53. Although both proteins contain a RING domain, only Mdm2 is functional as an E3 ubiquitin ligase (Marine and Jochemsen, 2005) .
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DNA damage DNA damage efficiently induces a p53 response, in part through the activation of ATM/ATR kinases that result in the phosphorylation of p53, Mdm2 and MdmX. While phosphorylation of p53 and Mdm2 can inhibit the interaction between these two proteins, allowing the stabilization of p53 (Shieh et al., 1997; Siliciano et al., 1997; Banin et al., 1998; Khosravi et al., 1999; de Toledo et al., 2000; Sakaguchi et al., 2000; Maya et al., 2001) , phosphorylation of Mdm2 and MdmX also enhances the degradation of these proteins by reducing their association with HAUSP -further releasing p53 from this level of negative regulation (Cummins and Vogelstein, 2004; Li et al., 2004; Meulmeester et al., 2005a, b; Tang et al., 2006) . The COP1 ubiquitin ligase is also phosphorylated in an ATM-dependent fashion, leading to a dissociation of COP1 from p53 and so promoting p53 stabilization (Dornan et al., 2006) . In addition to the stabilization of p53, DNA damage-induced kinases may also play a role in activating p53 as a transcription factor, in part by promoting acetylation within the C-terminus of p53 (Lambert et al., 1998; Dumaz and Meek, 1999) .
Oncogene activation
One of the key mediators of oncogene-induced activation of p53 is p14 ARF (ARF) (recently reviewed in Sherr, 2006) . ARF, the alternate reading frame product of the p16/ INK4A locus, has been shown to have a variety of functions, with one of its key roles being the binding and inhibition of Mdm2. Loss of ARF can, to a large degree, substitute for loss of p53 in tumour development, suggesting that disabling this pathway of p53 activation is critical for cancer progression (Sherr, 2006) . Interestingly, loss of ARF does not prevent the activation of p53 in response to DNA damage, indicating that these are independentalthough clearly complementary and cooperative -signals to p53 (Stott et al., 1998; Kamijo et al., 1999) .
Ribosomal stress A number of ribosomal proteins, in particular L5, L11 and L23, have been shown to bind and inhibit Mdm2, thereby stabilizing and activating p53 (Lohrum et al., 2003; Zhang et al., 2003; . Indeed, treating cells with siRNA for L5 or L11 abrogates the induction of p53 in response to ribosomal stress, such as treatment with the RNA PolI inhibitor Actinomycin D (Bhat et al., 2004; . Physiological stimuli that have been shown to signal through the ribosomal stress pathway include serum starvation and cell-cell contact growth inhibition (Bhat et al., 2004) . Furthermore, inactivation of the transcription initiation factor 1A (TIF-IA), which is responsible for regulating the transcription of ribosomal RNA, induced binding of ribosomal proteins, including L11, to Mdm2, and the activation of p53 (Yuan et al., 2005) . Interestingly, the DNA damage signal to p53 also depends on nucleolar disruption (Rubbi and Milner, 2003) , suggesting a cooperation between kinases such as ATM/ATR and the ribosomal proteins. Ribosomal stress also enhances Mdm2-mediated degradation of MdmX, thereby releasing p53 from the negative regulation exerted by both proteins . While somewhat surprising, a clear role for ribosomal proteins in tumour suppressor pathways has also been established in zebrafish (Amsterdam et al., 2004) . The importance of these interactions in humans is also strongly suggested by the observation that cancer associated mutations in Mdm2 can prevent the interaction with L11 and L5 (Lindstrom et al., 2006) .
Cell-cell contacts
Another DNA-damage independent stimulus that leads to the activation of p53 is the loss of cell-matrix adhesion (reviewed in Grossmann (2002)). Loss of cellcell or cell-matrix contact occurs in migrating cells, especially when they enter the blood or lymph systems. In non-transformed cells, the loss of adhesion can trigger a form of apoptosis known as anoikis, which in some cell types has been shown to be p53 dependent. The ability to overcome anoikis may be an important step in tumour progression towards metastasis, and the loss of p53 is critical for this step in some cell types. The PTEN phosphatase, a target of p53, appears to play an important role, as the expression of PTEN in a p53 null background can restore the sensitivity to anoikis (Lu et al., 1999) . While the pathways leading to the activation of p53 in response to loss of adhesion are not clear, signalling through integrins can provide adhesionassociated survival signals to prevent the activation of p53 and cell death .
Hypoxia
Cells at the centre of expanding tumours often experience hypoxic conditions, due to the lack of angiogenesis to provide the ever increasing mass of cells with oxygen. Hypoxia activates p53 and stimulates p53-dependent apoptosis through mechanisms thatalthough not clear -appear to involve ATR, HIF 1a (hypoxia inducible factor) and VHL (von HippelLindau) (reviewed in Hammond and Giaccia, 2005) . Under normoxic conditions, HIF 1a is degraded through its interaction with VHL (Maxwell et al., 1999; Semenza, 2001) . Hypoxic or anoxic conditions promote the stabilization of HIF 1a by disrupting its interaction with VHL, and HIF 1a is able to bind p53 and promote its stabilization. Furthermore, VHL can also interact with p53 directly and promote p53 phosphorylation and acetylation, leading to the activation (Roe et al., 2006) . Interestingly, p53 induced by hypoxia shows a different pattern of target gene activation than seen following DNA damage (reviewed in Hammond and Giaccia (2005) , Krieg et al. (2006) ), suggesting that p53 may mediate a quite different response to hypoxia compared to other stress signals.
All signals are not equal
The realization that different stress signals can activate p53 through different pathways raises the question -are all these pathways equally important for tumour suppression? The DNA damage pathway has been shown to be constitutively active in tumours (DiTullio et al., 2002) , with evidence that the DNA damage response pathways are activated even before cells become tumorigenic. The resultant activation of p53 in early hyperplastic and pre-cancerous lesions appears to prevent the formation of tumours (Bartkova et al., 2005; Gorgoulis et al., 2005) , highlighting the importance of DNA damage pathways.
However, recent studies have also suggested the signalling through the ARF pathway -which is required to respond to oncogene activation but not DNA damage -is the response that is critical for tumour suppression. These studies suggest that while the DNA damageinduced activation of p53 certainly produces a strong response, this is not necessary for tumour suppression, which requires ARF and is therefore more likely to reflect the induction of p53 in response to oncogene activation (Christophorou et al., 2006; Efeyan et al., 2006) (Figure 2 ). Is it possible that activation of p53 by acute genotoxic stress is only deleterious to health, leading to radiation sickness that might be avoided in the absence of functional p53? p53 may become beneficial only once most of the damage has been resolved, to drive elimination of the rare cells that have acquired an oncogenic mutation. Further studies of the relative contribution of each of the p53 activating signals will be very revealing.
Regulation of p53 stability and cancer therapy
A large number of human tumours retain wild-type p53, and many of these show evidence of perturbations in the pathways that allow stabilization and activation of p53 in response to stress. These pathways present attractive targets for developing treatments that could restore p53 function in these tumours. Examples of these include drugs that might inhibit the interaction between p53 and Mdm2, such as Nutlin-3 (Vassilev et al., 2004) or RITA (Issaeva et al., 2004) . While there is some controversy concerning the mechanisms of function of RITA (Krajewski et al., 2005) , both compounds allow for the stabilization of active p53 and show promising results in animal tumour models. Interestingly, Nutlin-3 does not efficiently block the interaction between p53 and MdmX, resulting in inefficient activation of p53 in tumours overexpressing MdmX (Hu et al., 2006; Patton et al., 2006) . However, other studies have suggested that in some cells, Nutlin-3 treatment can result in the degradation of MdmX (Wade et al., 2006) -possibly through the action of Mdm2 released from p53 -and so the utility of Nutlin-3 as a therapy is likely to be strongly context dependent.
Other approaches to reactivating p53 have included directly targeting the Mdm2 E3 ligase activity (Yang et al., 2005) ; and the direct targeting of MdmX or HAUSP may also prove fruitful. It is clear that as the secrets of p53 regulation are uncovered, more potential targets for the design of novel therapies will be revealed. It seems likely that the next 40 000 reports on p53 will be as exciting as the first. Regulation of p53 stability and p53-dependent apoptosis by Figure 2 Activation and response to p53. p53 is activated by many stress signals that can differ in type and severity, which can lead to the activation of different responses, not all of which are clearly beneficial to the organism. Induction of cell death or senescence in response to severe DNA damage or oncogene activation are thought to be amongst the most important mechanisms of p53-mediated tumour suppression. While there is evidence that DNA damage signalling in premalignancies activates p53 and contributes to tumour suppression, other work has suggested that the response to acute genotoxic stress results predominantly in toxicity, and that the response to oncogene activation plays the most important role in tumour suppression. In addition to these two acute insults, p53 responds to a variety of milder, constitutive stresses -such as the generation of ROS by normal metabolism -and under these conditions p53 functions to allow survival and repair of the damage, and so may even contribute to the longevity of the organism.
